Regado Biosciences, a US-based thrombosis treatment company backed by local drugs group Baxter’s corporate venturing unit, plans to raise $75m in its flotation on the Nasdaq stock exchange.
Investment banks Cowan and BMO Capital Markets are advising the initial public offering (IPO), with legal counsel from Lowenstein Sandler and Goodwin Procter.
Shareholders in the pre-revenue company include venture capital firms Domain Associates (19.2%), Quaker BioVentures (12.7%), Edmond de Rothschild Investment Partners (12.4%), RMI Investments (14.2%) and Aurora Funds (7.9%).
Regardo has raised about $122m in private funding up until its series E round, according to its regulatory filing.
In December, RusnanoMedInvest, a subsidiary of the state-run Russian investment firm Rusnano, led a $51m series E round into Regado.
There was also participation in this E round from new investor Baxter Healthcare’s venture initiative, Baxter Ventures.
In 2009 Regado raised $40m in a Series D round from Edmond de Rothschild Venture Capital, Domain Associates, Quaker BioVentures, The Aurora Funds and Caxton Advantage Life Sciences Fund.